While Enliven Therapeutics Inc has overperformed by 1.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ELVN rose by 85.06%, with highs and lows ranging from $30.03 to $10.90, whereas the simple moving average jumped by 3.66% in the last 200 days.
On December 13, 2024, BTIG Research started tracking Enliven Therapeutics Inc (NASDAQ: ELVN) recommending Buy. A report published by H.C. Wainwright on September 09, 2024, Initiated its previous ‘Buy’ rating for ELVN. Robert W. Baird also rated ELVN shares as ‘Outperform’, setting a target price of $32 on the company’s shares in an initiating report dated June 11, 2024. Mizuho Initiated an Buy rating on April 09, 2024, and assigned a price target of $34. Jefferies initiated its ‘Buy’ rating for ELVN, as published in its report on March 29, 2023.
Analysis of Enliven Therapeutics Inc (ELVN)
In order to gain a clear picture of Enliven Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -30.98% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 17.44, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 218.16K can be a very valuable indicator of volatility for ELVN stock. On a monthly basis, the volatility of the stock is set at 6.62%, whereas on a weekly basis, it is put at 6.71%, with a gain of 7.33% over the past seven days. Furthermore, long-term investors anticipate a median target price of $37.71, showing growth from the present price of $24.15, which can serve as yet another indication of whether ELVN is worth investing in or should be passed over.
How Do You Analyze Enliven Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 36.85%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 67.66% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ELVN shares are owned by institutional investors to the tune of 67.66% at present.